Management of NETs: Other Medical Therapies
Interferon therapy is generally recommended as a second-line approach in patients with functioning NETs and low proliferation. The effect of interferons on symptom control is similar to that of somatostatin analogues and they may have greater antiproliferative activity; however, they do not act as rapidly and have a less favorable safety profile (fever, fatigue, anorexia and weight loss are commonly reported). IFN-α is the most widely studied and a pooled analysis of trials investigating this agent in patients with NETs demonstrated that approximately 40% had biochemical responses (which is comparable to that observed with octreotide and lanreotide) whilst approximately 10% had objective tumor responses. Although the number of trials is small and studies may be underpowered, combination of IFN-α with somatostatin analogues might have a synergistic effect.[14,67–69]
Expert Rev Endocrinol Metab. 2011;6(1):49-62. © 2011 Expert Reviews Ltd.
Cite this: Management of Neuroendocrine Tumors: Current and Future Therapies - Medscape - Jan 01, 2011.